TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04883411: CEM-Plate and CEM-Cage First-In-Human Use Efficacy Study

Sponsor: ReVivo Medical, Corp. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 50 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$896,400

Rescue Site Savings

+$597,600

Unlock Full NCT04883411 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04883411 Rescue Dossier →